Anti-VEGF in treatment of central retinal vein occlusion

Collegium Antropologicum

Volumn 34, Issue SUPPL. 2, 2010, Pages 69-72

  Lazić, Ratimir ^a   Boras, Ivan ^a   Vlašić, Marko ^a   Gabrić, Nikica ^a   Tomić, Zoran ^a  

^a Eye Clinic Svjetlost   (Croatia)

Author keywords

Anti vascular endothelial growth factor therapy; Bevacizumab; Central retinal vein occlusion; Macular edema

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 77955600897     PISSN: 03506134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. MITCHELL P, SMITH W, CHANG A, Arch Ophthalmol 114 (1996) 1243.
2. KLEIN R, KLEIN BE, MOSS SE, MEUER SM, Trans Am Ophthalmol Soc 98 (2000) 133.
3. GROUP TCVOS, Arch Ophthalmol 111 (1993) 1087.
4. GROUP TCVOS, Arch Ophthalmol 115 (1997) 486.
5. HAYREH SS, Ophthalmol Clin North Am 11 (1998) 559.
6. GREEN W, CHAN C, HUTCHINS G, Retina 1 (1981) 27.
7. PE'ER J, FOLBERG R, ITIN A, Ophthalmology 105 (1998) 412.
8. BOYD SR, ZACHARY I, CHAKRAVARTHY U, Arch Ophthalmol 120 (2002) 1644.